International Advocacy

“I’ve never been a farmer,” Bill Gates confessed at The Chicago Council’s Symposium on Global Agriculture and Food Security. “Until recently, I rarely set foot on a farm.”

WASHINGTON, D.C. (Tuesday, April 19, 2011) - The Biotechnology Industry Organization (BIO) announced today that Dr. Jörg Reinhardt, CEO of Bayer HealthCare, will provide the keynote address at the BIO China International Conference to be held October 12-13 in Shanghai, China. The event will bring together biotechnology and pharmaceutical leaders to explore business opportunities with life science companies in China.

Scientific American will release the third annual Worldview: A Global Biotechnology Perspective at this year's BIO International Convention.

BIO is committed to increased access to biologic medicines for patients throughout the world. 

You might have heard that the Prince of Wales, just days after hosting the Royal Wedding, paid us a visit here in Washington.  Prince Charles, a long-time organic food advocate and self-described environmentalist, was here to speak at a Washington Post symposium on the Future of Food.

Prince Charles likes to talk about “sustainability” so much that he used a version of the word 32 times in his recent speech about farming at Georgetown University.

The world’s largest biotech hubs are busy planning their delegations’ visits to the  BIO International Convention  next month. The international program at the Convention will be one of the most robust to date, with International Case Studies, breakout sessions focused on globalization and Super Sessions focused on the emerging markets.

Scientific American will release the third annual Worldview: A Global Biotechnology Perspective at this year’s BIO International Convention.

Three biotech luminaries who have succeeded against all odds share their experiences building a biotech company from the ground up in Brazil, China and India.

As we celebrate World Health Day today, it is an opportunity to remember that vaccines represent one of the most important global health investments.

Fifteen years after Dolly, the first mammal to be cloned from an adult cell rather than an embryo, made headlines, the process of livestock cloning is increasingly gaining acceptance as a viable means of satisfying demand for sustainable food production.

Patent systems can provide an advantage to society by rewarding the development of new inventions, promoting the advancement of technology and protecting the investor.  Patents often are the most important, and sometimes only, asset of a biotech company. Patents and related rights must be obtained in a timely and predictable manner and the ability to enforce those patents is critical.

Overhauled BIOTradeStatus lets users search for the latest information on hundreds of products.

ISAAA data shows countries around the world have embraced agricultural biotechnology.

Letters, Testimony & Comments

June 7 2013
BIO applauds the government of Brazil for taking steps towards developing regulatory requirements to ensure patients suffering from rare diseases have access to treatment.   
June 3 2013
BIO appreciates the opportunity to respond to the Request for Comments issued by the U.S. Trade Representative on objectives to be pursued in the negotiation of a Transatlantic Trade and Investment Partnership (TTIP) agreement. 
March 21 2013
BIO commends the Government of Peru for its endeavor to create a pathway for the approval of biological and biotechnological products. Peru is a growing market for biotechnology products and with the implementation of the US-Peru TPA, it promises to become an even bigger market.
February 22 2013
BIO commends the government of Colombia for taking steps towards developing regulatory requirements for the registry of medicines of biological origin. Many elements of the third draft appear to have addressed BIO's previous comments with respect to clarity of structure and definitions of terms, as well as expectations for data requirements.   
February 8 2013
Biotechnology companies provide unique benefits to the United States and the world. In the health care sector alone, the industry has developed and commercialized more than 300 biotechnology drugs and diagnostics and there are over 400 products in the pipeline.

Press Releases

April 8 2013
Strong Intellectual Property Protection Is Vital For The Life Sciences Industry.
July 23 2012
Groups issue booklet to help biotechnology and pharmaceutical companies identify pipeline medicines with doping potential.
June 6 2012
The report will be released at a Super Session, titled "International Leaders Share Their Worldview: Scientific American's Regional Bio-Innovation Scorecard."
April 5 2012
Centric Health Resources and the National Organization for Rare Disorders (NORD), Co-organizersAlnylam Pharmaceuticals, Genzyme, a Sanofi Company and Millennium: The Takeda Oncology Company, Co-sponsors
October 5 2011
BIO welcomed the transmission of the Korea-U.S. Free Trade Agreement (KORUS FTA) by President Obama to the Congress earlier this week.